← Back to Search

Prostaglandin Analog

Xalatan --> Apo-/Co-Latanoprost for Primary Open Angle Glaucoma

Phase 4
Waitlist Available
Led By David B Yan, M.D., F.R.C.S. (C)
Research Sponsored by Dr. David Yan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients ≥ 18 years old, diagnosed with primary open angle glaucoma or ocular hypertension
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights

Study Summary

The purpose of the study is to provide evidence that the efficacy of Xalatan will be superior to Apo-latanoprost and Co-latanoprost in the reduction of intraocular pressure in patients with primary open angle glaucoma. The study will also aim to prove the tolerability of Xalatan in terms of ocular hyperemia will be equivalent to its generic counterparts.

Eligible Conditions
  • Primary Open Angle Glaucoma
  • Glaucoma
  • Ocular Hypertension

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intraocular Pressure
Secondary outcome measures
Ocular Hyperemia

Trial Design

2Treatment groups
Experimental Treatment
Group I: Xalatan --> Apo-/Co-LatanoprostExperimental Treatment3 Interventions
Patients in this arm will be prescribed Xalatan for the first four week period of the study and one of the generics, Apo- or Co-Latanoprost, for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
Group II: Apo-/Co-Latanoprost --> XalatanExperimental Treatment3 Interventions
Patients in this arm will be prescribed one of the generics, Apo- or Co-Latanoprost, for the first four week period of the study and Xalatan for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Latanoprost
FDA approved

Find a Location

Who is running the clinical trial?

AllerganIndustry Sponsor
781 Previous Clinical Trials
276,509 Total Patients Enrolled
Dr. David YanLead Sponsor
David B Yan, M.D., F.R.C.S. (C)Principal InvestigatorOphthalmic Diagnostic Services

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
Dr. David Yan 2015. "A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02792803.
All > Glaucoma
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top